{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride+Injection+as+Placebo&page=2",
    "query": {
      "intervention": "0.9% Sodium Chloride Injection as Placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 234,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride+Injection+as+Placebo&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.9%25+Sodium+Chloride+Injection+as+Placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T08:02:36.885Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01422161",
      "title": "Study of Botulinum Toxin and Recovery of Hand Function After Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Stroke With Hemiparesis"
      ],
      "interventions": [
        {
          "name": "Botulinum Toxin commonly known as BOTOX®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2010-04",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2019-06-20",
      "last_synced_at": "2026-10-09T08:02:36.885Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01422161"
    },
    {
      "nct_id": "NCT06451120",
      "title": "Platelet Rich Plasma Injections In Young And Old Human Subjects",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis",
        "Articular Cartilage",
        "Musculoskeletal Disorders"
      ],
      "interventions": [
        {
          "name": "Platelet-Rich Plasma (PRP) Injections",
          "type": "DRUG"
        },
        {
          "name": "Centrifuge",
          "type": "DEVICE"
        },
        {
          "name": "Control saline injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-06-01",
      "completion_date": "2027-02-16",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-10-09T08:02:36.885Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06451120"
    },
    {
      "nct_id": "NCT04134728",
      "title": "Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "GSK3196165 (Otilimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sarilumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to GSK3196165/ Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "csDMARDs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 550,
      "start_date": "2019-10-31",
      "completion_date": "2022-02-01",
      "has_results": true,
      "last_update_posted_date": "2023-07-17",
      "last_synced_at": "2026-10-09T08:02:36.885Z",
      "location_count": 46,
      "location_summary": "Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04134728"
    },
    {
      "nct_id": "NCT04761822",
      "title": "COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV Infection",
        "COVID-19",
        "Allergic Reaction",
        "Mast Cell Disorder"
      ],
      "interventions": [
        {
          "name": "Moderna COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pfizer-BioNTech COVID-19 Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Years and older"
      },
      "enrollment_count": 746,
      "start_date": "2021-04-07",
      "completion_date": "2022-04-27",
      "has_results": true,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-10-09T08:02:36.885Z",
      "location_count": 29,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04761822"
    },
    {
      "nct_id": "NCT07282665",
      "title": "A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Clostridoides Difficile Associated Disease"
      ],
      "interventions": [
        {
          "name": "C.difficile vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 32500,
      "start_date": "2025-12-10",
      "completion_date": "2029-06-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-09T08:02:36.885Z",
      "location_count": 141,
      "location_summary": "Athens, Alabama • Guntersville, Alabama • Huntsville, Alabama + 89 more",
      "locations": [
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chinle",
          "state": "Arizona"
        },
        {
          "city": "Chinle",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07282665"
    },
    {
      "nct_id": "NCT02037555",
      "title": "Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cardiac Surgery",
        "Cardiopulmonary Bypass"
      ],
      "interventions": [
        {
          "name": "AT-III (Human)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 425,
      "start_date": "2014-06-26",
      "completion_date": "2018-01-25",
      "has_results": true,
      "last_update_posted_date": "2019-03-15",
      "last_synced_at": "2026-10-09T08:02:36.885Z",
      "location_count": 41,
      "location_summary": "Orange, California • San Francisco, California • Stanford, California + 36 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02037555"
    },
    {
      "nct_id": "NCT02548494",
      "title": "Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 1",
        "Diabetic Ketoacidosis"
      ],
      "interventions": [
        {
          "name": "Glargine",
          "type": "DRUG"
        },
        {
          "name": "IV insulin",
          "type": "DRUG"
        },
        {
          "name": "Electrolyte Correction",
          "type": "OTHER"
        },
        {
          "name": "Correction of Fluid Loss",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Chattanooga-Hamilton County Hospital Authority",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 17,
      "start_date": "2015-11",
      "completion_date": "2019-02-01",
      "has_results": false,
      "last_update_posted_date": "2020-09-23",
      "last_synced_at": "2026-10-09T08:02:36.885Z",
      "location_count": 1,
      "location_summary": "Chattanooga, Tennessee",
      "locations": [
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02548494"
    },
    {
      "nct_id": "NCT02658877",
      "title": "Sputum-derived Cellular Targets After Xolair (Omalizumab)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 3,
      "start_date": "2016-01",
      "completion_date": "2018-07-19",
      "has_results": true,
      "last_update_posted_date": "2019-09-30",
      "last_synced_at": "2026-10-09T08:02:36.885Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02658877"
    },
    {
      "nct_id": "NCT07675629",
      "title": "Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C))",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alhydrogel adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLA-SE adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for DNA Vaccines, Protein Vaccines and Adjuvants",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Worcester HIV Vaccine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 126,
      "start_date": "2026-09-01",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-10-09T08:02:36.885Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07675629"
    },
    {
      "nct_id": "NCT05698095",
      "title": "Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics",
        "Safety",
        "Tolerability"
      ],
      "interventions": [
        {
          "name": "5-methoxy-N,N-dimethyltryptamine succinate salt",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Usona Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 54,
      "start_date": "2022-12-27",
      "completion_date": "2023-09-07",
      "has_results": false,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-10-09T08:02:36.885Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05698095"
    }
  ]
}